Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02442362

TOF Versus SOX in Metastatic Gastric Cancer

Paclitaxel/Oxaliplatin/Fluorouracil (TOF) Regimen Versus S-1/Oxaliplatin (SOX) Regimen Metastatic Gastric Cancer Patients

Sponsor: The First People's Hospital of Changzhou

Conditions Gastric Cancer

Interventions oxaliplatin+S1 paclitaxel+oxaliplatin+fluorouracil

Updated 5 times since 2017 Last updated: May 12, 2015 Started: Jan 31, 2012 Primary completion: Jan 31, 2014 Completion: Jun 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02442362, this PHASE2/PHASE3 trial focuses on Gastric Cancer and remains completed. Sponsored by The First People's Hospital of Changzhou, it has been updated 5 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The First People's Hospital of Changzhou

Data source: The First People's Hospital of Changzhou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.